782 related articles for article (PubMed ID: 27183299)
21. Extended-release dexmethylphenidate 30 mg/d versus 20 mg/d: duration of attention, behavior, and performance benefits in children with attention-deficit/hyperactivity disorder.
Silva RR; Brams M; McCague K; Pestreich L; Muniz R
Clin Neuropharmacol; 2013; 36(4):117-21. PubMed ID: 23860345
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control.
Brams M; Turnbow J; Pestreich L; Giblin J; Childress A; McCague K; Muniz R
J Clin Psychopharmacol; 2012 Oct; 32(5):637-44. PubMed ID: 22926597
[TBL] [Abstract][Full Text] [Related]
24. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
Silva RR; Muniz R; Pestreich L; Brams M; Mao AR; Childress A; Wang J
J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, Safety, and Tolerability of a Novel Methylphenidate Extended-Release Oral Suspension (MEROS) in ADHD.
Robb AS; Findling RL; Childress AC; Berry SA; Belden HW; Wigal SB
J Atten Disord; 2017 Dec; 21(14):1180-1191. PubMed ID: 24874348
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day.
Faraone SV; Childress AC; Gomeni R; Rafla E; Kando JC; Dansie L; Naik P; Pardo A
J Child Adolesc Psychopharmacol; 2023 Feb; 33(1):14-19. PubMed ID: 36730749
[No Abstract] [Full Text] [Related]
28. Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study.
Wigal SB; Childress A; Berry SA; Belden HW; Chappell P; Wajsbrot DB; Nagraj P; Abbas R; Palumbo D
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):314-321. PubMed ID: 29641237
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
Wigal S; Lopez F; Frick G; Yan B; Robertson B; Madhoo M
Postgrad Med; 2019 Apr; 131(3):212-224. PubMed ID: 30681017
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
Wigal SB; Gupta S; Heverin E; Starr HL
J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
[TBL] [Abstract][Full Text] [Related]
32. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
Childress A; Stark JG; McMahen R; Engelking D; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
[TBL] [Abstract][Full Text] [Related]
35. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Greenhill LL; Findling RL; Swanson JM;
Pediatrics; 2002 Mar; 109(3):E39. PubMed ID: 11875167
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
[TBL] [Abstract][Full Text] [Related]
37. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder.
Wigal SB; Wigal T; Schuck S; Brams M; Williamson D; Armstrong RB; Starr HL
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):121-31. PubMed ID: 21488750
[TBL] [Abstract][Full Text] [Related]
38. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.
Biederman J; Boellner SW; Childress A; Lopez FA; Krishnan S; Zhang Y
Biol Psychiatry; 2007 Nov; 62(9):970-6. PubMed ID: 17631866
[TBL] [Abstract][Full Text] [Related]
39. Measuring methylphenidate response in attention-deficit/hyperactvity disorder: how are laboratory classroom-based measures related to parent ratings?
Sonuga-Barke EJ; Coghill D; DeBacker M; Swanson J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):691-8. PubMed ID: 20035587
[TBL] [Abstract][Full Text] [Related]
40. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
Weisler RH; Stark JG; Sikes C
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]